The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Role of the PD-1 Pathway in the Immune Response
Open accessAbstract
Understanding immunoregulatory mechanisms is essential for the development of novel interventions to improve long-term allograft survival. Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, have emerged as critical inhibitory signaling pathways that regulate T cell response and maintain peripheral tolerance. PD-1 signaling inhibits alloreactive T cell activation, and can promote induced regulatory T cell development. Furthermore, the upregulation of PD-L1 on nonhematopoietic cells of the allograft may actively participate in the inhibition of immune responses and provide tissue-specific protection. In murine transplant models, this pathway has been shown to be critical for the induction and maintenance of graft tolerance. In this review, we discuss the current knowledge of the immunoregulatory functions of PD-1 and its ligands and their therapeutic potential in transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“T cell proliferation and function can also be enhanced by blocking signalling through the inhibitory receptors such as PD-1 [77].”
From Senescence of T Lymphocytes: Implications for Enhancing Human Immunity (2016) · cites this paper as [77]
In the citing paper
“and this is an important strategic point because the use of PD-1/PD-L1 therapy has been reported to impair Treg cells in the renal allograft.173”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,475 · cited 1×
“Regulatory T cells Regulatory T cell populations are critical for the maintenance of peripheral tolerance, are potent inhibitors of many immune responses and play an important role in the prevention of graft rejection (64,65).”
BackgroundPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 2×
“PD-1 is inducibly expressed by T cells and B cells after activation (7) as well as natural killer T (NKT) cells, NK cells, activated monocytes and some subsets of dendritic cells (DCs) [reviewed in (8)].”
BackgroundSelf-citationFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 2×
“PD-L1 is expressed constitutively on murine T and B cells, DCs, macrophages, mesenchymal stem cells and bone marrow-derived mast cells (12,18), and induced to higher levels by inflammation.”
BackgroundThe Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,090
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 2×
“Therefore, additional markers such as CD223 (LAG-3), CD244 (2B4) and TIM-3 might be required to correctly identify this subset of T cells (121).”
BackgroundBennett, C. L., Christie, J., Ramsdell, F., Brunkow, M., Ferguson, P., Whitesell, L., Kelly, T., Saulsbury, F., Chance, P., & Ochs, H. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,576 · cited 1×
“CD4+Foxp3+ Tregs, the most widely studied suppressive T cell population, are critical for peripheral tolerance as illustrated by the fatal autoimmune condition of scurfy mice and the human immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), both caused by mutations in the foxp3 gene (66,67…”
Background
Research works printed but not linked: 1
- McDermott, 2011, A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 in patients with RCC and other advanced refractory malignancies, J Clin Oncol, 29
Cited by
Sorted by citations
Items 401–443 of 443
Agustina, H., Aryanti, A., & Hernowo, B. S. (2022) · Indonesian Journal of Cancer · doi:10.33371/ijoc.v16i2.867
Immune Checkpoints: The Rising Branch in Cancer Immunotherapy
Nurlaila, I. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.108656
Lithium salts as a possible therapeutic option for SARS CoV 2 infection
Soriano-Torres, O. (2022) · West Indian Journal of Immunology · doi:10.53069/wiji/0000001
Atezolizumabe mais Bevacizumabe como Ponte para Transplante Hepático no Carcinoma Hepatocelular
Solino, G. A., Ferreira, R. P. C., D′Albuquerque, L. A. C., Farias, A. Q., Trindade, L. Z., de Vasconcellos, V. F., & Pacheco, M. P. (2023) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v26i1.444_port
Oh, W., Kim, A. M. J., Dhawan, D., Kirkham, P. M., Ostafe, R., Franco, J., Aryal, U. K., Carnahan, R. H., Patsekin, V., Robinson, J. P., et al. (2023) · doi:10.1158/2767-9764.c.6647231.v1
Flow cytometry analysis of PD1 expression on rat blood CD3+ lymphocytes stimulated by CD3 antibodies
Khramova, T., Beduleva, L., Владимировна, Ф. К., & Николаевна, А. Н. (2023) · Russian Journal of Immunology · doi:10.46235/1028-7221-9639-fca
Osmana, M. M., El-Badaway, O. H. B., Zahran, A. M., Salem, M. A. M., & Abdelraheemd, A. G. (2023) · Pan Arab Journal of Rhinology · doi:10.58595/2090-7559.1208
Pajuelo, A. (2023) · Science Insights · doi:10.15354/si.23.re838
Sham, N. F. R., Hasbullah, H. H., Hasani, N. A. H., Hasan, N., Othman, S., Osman, N. J., Karim, M. K. A., Fuad, S. B. S. A., & Ibahim, M. J. (2024) · Biomedical Research and Therapy · doi:10.15419/bmrat.v11i2.864
Immunotherapy in the Solid Organ Transplant Recipient
Liu, A., Barbir, E., Kukla, A., & Watt, K. D. (2024) · Springer eBooks · doi:10.1007/978-3-031-59475-5_13
IMmuneCite: an integrated workflow for analysis of immune enriched spatial proteomic dataPreprint
Barbetta, A., Bangerth, S., Lee, J. T. C., Rocque, B., Torres, E. T. R., Kohli, R., Akbari, O., & Emamaullee, J. A. (2024) · Research Square · doi:10.21203/rs.3.rs-4571625/v2
Zhang, Q., An, N., Li, X., Zhang, P., Wang, K., & Zha, B. (2024) · Research Square · doi:10.21203/rs.3.rs-4735688/v1
Resistance to chimeric antigen receptor T cells (CAR-T)
Kaşmer, R., & Karakaş, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21790-6.00007-9
The Know-How Post-Transplant Skin Cancer for Immunotherapy and Target Therapies
Denaro, N., Passoni, E., Murgia, G., Solinas, C., Nazzaro, G., Marzano, A. V., Campise, M., & Garrone, O. (2025) · Oncology · doi:10.1159/000543801
“Renal tubular PD-L1 suppresses alloreactive human T cell [14, 15].”
Immune Checkpoint Inhibitors in Therapeutics and their Adverse Effect Profile: A Review
Adiga, S., Kishore, B. A., & Vasishta, S. (2025) · The Open Biomedical Engineering Journal · doi:10.2174/0118741207369739250423073032
SOLUBLE FORMS OF PD-1 RECEPTOR AND PD-L1 LIGAND IN PATIENTS WITH RENAL CELL CARCINOMA
Sokolov, N., Kovaleva, O. V., Bezhanova, S. D., Klimanov, I., Matveev, V. B., & Кушлинский, Н. Е. (2025) · Problems of Biological Medical and Pharmaceutical Chemistry · doi:10.29296/25877313-2025-04-07
Bushara, O., D’Orleans, C. C., Kadakia, Y. H., Alur, R., Devaro, D., & Singhal, S. K. (2025) · Pathobiology · doi:10.1159/000546745
“It allows for the cessation of runaway inflammatory immune responses and thus limits local tissue damage and continued use of immune resources [131, 132].”
Rutakingirwa, M. K., Ssebambulidde, K., Okurut, S., Kwizera, R., Nabwana, M., Gakuru, J., Ndyetukira, J. F., Mulwana, S., Nankungu, L., Tadeo, K. K., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf449 · Cited by 1
Tsuji, H., Lin, H.-Y., Kinoshita, S., Jinguji, H., Nakazawa, Y., Ogo, M., & Ohyama, M. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04764-x
“PD-L1 PD-L1 enhances allograft survival following allogeneic transplantation [44].”
Su, C., Wan, S., Ding, J., 倪观太, & Ding, H. (2024) · Figshare · doi:10.6084/m9.figshare.25621904
Carter, E. R., & Lee, J. M. (2021) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/ayetm32nyo
Genetic disruption of Pdcd-1 upstream enhancer boosts T cell function and antitumor responses
Jerin, C., Seo, W., & Nishikawa, H. (2026) · Immunology Letters · doi:10.1016/j.imlet.2026.107171 · Cited by 2
Involvement of the PD-1 pathway in the modulation of immune responses during allergic diseases
Mohamed, A. H., Al-Samawi, R. I., Jamali, M. C., Ali, S., Patel, A. A., Mustafa, A. E. M., Khairallah, A. S., Mansuri, N., Dutta, A. K., Sadikan, M. Z., et al. (2026) · Inflammation Research · doi:10.1007/s00011-026-02217-6
Genomics-Driven Immunotherapy: Advancing Cancer Treatment through Personalized Approaches
Kate, A. A., Desai, S. A., Sapkal, S. P., More, M. J., & Patel, V. P. (2026) · Current Genomics · doi:10.2174/0113892029403241260416110923
“PD-1 regulates T cell-mediated response by playing an important role in the programmed cell death signalling process [88].”
Amirian, N., Squires, A. M., Azanabor, L., Walker, C. A., Simmonds, M. J., & Rinaldi, C. R. (2026) · Cancers · doi:10.3390/cancers18111808
“…with its ligands, PD-L1 and PD-L2, initiates intrinsic signalling pathways that recruit tyrosine phosphatase, ultimately reducing antigen presentation to T cells [77], while the binding of CTLA-4 to its receptors, CD80 and CD86, blocks co-stimulatory signals required for T cell activation [78].”
Looser, R., Hofbauer, G. F. L., Golshayan, D., Nägeli, M., & Study, O. B. O. T. S. T. C. (2026) · Cancers · doi:10.3390/cancers18121918
“The PD-1 pathway, on the other hand, is important for long-term transplant survival [32].”
The immunological paradox: immune checkpoint inhibitors in liver transplantation
Ito, T., Okumura, S., Sakamoto, K., & Hatano, E. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03091-2
“[13–16].”
Almarghalani, N. A., Ganash, M., Alharbi, M. G., Abualfaraj, T., Alkayyal, A. A., & Mahmoud, A. B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1824087
“PD-1 is more widely expressed than CTLA-4 in several immune cell populations present in the TME, such as dendritic cells (DCs), natural killer (NK) cells, T cells, and B cells (41).”
Giannetti, M., Gobbo, M., Litti, L., Caligiuri, I., Rizzolio, F., Meneghetti, M., Mazzuca, C., & Palleschi, A. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.6c01076
Liu, Z., Zhu, X., Cheng, J., Li, K., Lou, Y., Sun, X., Fan, Y., Wang, M., Qian, H., Liu, Y., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.180867
Benam, S. R., Maleknia, S., Williams, K. E., Apétoh, L., & Shahbazi, R. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02784-4
“19 Upregulation of inhibitory and traf fi cking-associated genes (ITGA4, TSPAN2, LAIR1, TOX, TOX2) within Treg populations, together with elevated ABCG1, supports enhanced tissue retention and lipid ef fl ux programs characteristic of suppressive phenotypes.”
Du, J.-J., Liu, R., Chen, L., & Zhang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1879839
“…advantages: oral bioavailability, tunable pharmacokinetics (including shorter half-lives enabling rapid dose adjustment or discontinuation), and reduced risk of Fc-mediated effector functions — thereby mitigating off-target immune activation and improving therapeutic controllability (9 – 11).”
Jalali, P., Wu, A. Y., Alkhazna, S., Celaj, S., & Saeed, A. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105591
Rabet, H., & Hosseini, S. M. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102807
“Endothelial cells, epithelial cells, stromal cells, and infiltrating immune cells can express PD-L1, especially under the influence of inflammatory cytokines such as inter- feron-γ [10,47,51].”
InfluentialImmune Checkpoint Inhibitors and Related Immunotherapies
Machado, S., & Cardoso, A. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch007
dos Santos, R. L., Rosa, T. D. S., Sezana-Costa, S., Lisboa, S. R., Estivalet, M. A. M., Ferreira, C. E. S., de Melo, G. F., Deus, L. A., Adeirton, J., Souza, M. K., et al. (2026) · Frontiers in Nephrology · doi:10.3389/fneph.2026.1972911
Self-citationBudner, M., Torres, K., Opoka‐Winiarska, V., Lasota, A., Gdak, M., Mertowska, P., Mertowski, S., Gosik, K., Kang, M. S., Urbanowicz, T. K., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219488
Immunohistochemistry and Molecular Techniques
Goyal, A., Goyal, K., Nardi, V., Hoang, M. P., Carter, J. B., & Duncan, L. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-17217-0_3
Metadata
- Authors
- Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Riella, L.V.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 12
- Issue
- 10
- Pages
- 2575-2587
- ISSN
- 1600-6135 (ISSN-L)
- PMC
- PMC3784243
- OpenAlex
- W2144601357
- Cited by
- 444
- References
- 132
- Citations by year
- 2026: 25 · 2025: 25 · 2024: 39 · 2023: 35 · 2022: 33 · 2021: 40 · 2020: 38 · 2019: 36 · 2018: 42 · 2017: 50 · 2016: 25 · 2015: 22 · 2014: 21 · 2013: 13
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Transplantation (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Heart Association
- National Institute of Allergy and Infectious Diseases (R01AI051559, P01 AI 56299, R01 AI-51559, P01AI056299)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- PD-1 pathway, PD-L1, PD-L2, allograft tolerance, immune regulation, regulatory T cells, peripheral tolerance, graft survival
- MeSH terms
- Graft Survival, Humans, Immune Tolerance, Lymphocyte Activation, Signal Transduction, Organ Transplantation, T-Lymphocytes, Regulatory, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
